96 related articles for article (PubMed ID: 3484657)
1. Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer.
Hacene K; Desplaces A; Brunet M; Lidereau R; Bourguignat A; Oglobine J
Cancer; 1986 Jan; 57(2):245-50. PubMed ID: 3484657
[TBL] [Abstract][Full Text] [Related]
2. Unaltered immunocompetence in patients with non-disseminated breast cancer at the time of diagnosis.
Ludwig CU; Hartmann D; Landmann R; Wesp M; Rosenfelder G; Stucki D; Buser M; Obrecht JP
Cancer; 1985 Apr; 55(8):1673-8. PubMed ID: 3872158
[TBL] [Abstract][Full Text] [Related]
3. Presurgical serum immunoglobulin concentrations and the prognosis of operable breast cancer in women.
Ownby DR; Ownby HE; Bailey J; Frederick J; Tilley B; Brooks SC; Russo J; Heppner G; Brennan M
J Natl Cancer Inst; 1985 Oct; 75(4):655-63. PubMed ID: 3862898
[TBL] [Abstract][Full Text] [Related]
4. E-rosette forming lymphocytes and serum immunoglobulins in breast cancer patients.
Singh RP; Singh VP; Udupa KN
Mater Med Pol; 1991; 23(3):179-81. PubMed ID: 1842710
[TBL] [Abstract][Full Text] [Related]
5. Blood lymphocyte counts with subset analysis in operable breast cancer. Relation to the extent of tumor disease and prognosis.
Rotstein S; Blomgren H; Petrini B; Wasserman J; Nilsson B; Baral E
Cancer; 1985 Sep; 56(6):1413-9. PubMed ID: 4027876
[TBL] [Abstract][Full Text] [Related]
6. [Immunologic response and prognosis in patients with breast cancer. II. Prognostic value of morphological and functional indicators of cellular response].
Smolak K
Nowotwory; 1984; 34(1):21-30. PubMed ID: 6330700
[No Abstract] [Full Text] [Related]
7. Prognostic value of some parameters of cellular immunity in breast cancer patients.
Seremet M; Rudolf M; Hrsak M; Kastelan M
Acta Med Croatica; 1992; 46(1):9-13. PubMed ID: 1380363
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
[TBL] [Abstract][Full Text] [Related]
9. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors affecting disease-free survival in patients at age 35 or younger with invasive breast cancer.
Koca B; Kuru B; Karabicak I; Yürüker SS; Ozen N
Ann Ital Chir; 2014; 85(3):249-53. PubMed ID: 25074433
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
12. Ratios of involved nodes in early breast cancer.
Vinh-Hung V; Verschraegen C; Promish DI; Cserni G; Van de Steene J; Tai P; Vlastos G; Voordeckers M; Storme G; Royce M
Breast Cancer Res; 2004; 6(6):R680-8. PubMed ID: 15535850
[TBL] [Abstract][Full Text] [Related]
13. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
[TBL] [Abstract][Full Text] [Related]
14. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
15. Immunological characterization of mononuclear cells in peripheral blood and regional lymph nodes of breast cancer patients.
Heidenreich W; Jagla K; Schüssler J; Börner P; Dehnhard F; Kalden JR; Leibold W; Peter HH; Deicher H
Cancer; 1979 Apr; 43(4):1308-13. PubMed ID: 376089
[TBL] [Abstract][Full Text] [Related]
16. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes.
Duraker N; Caynak ZC
Cancer; 2005 Aug; 104(4):700-7. PubMed ID: 16003773
[TBL] [Abstract][Full Text] [Related]
18. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment Prognostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Vascular, Texture, Shape, and Size Parameters Compared With Traditional Survival Indicators Obtained From Locally Advanced Breast Cancer Patients.
Pickles MD; Lowry M; Gibbs P
Invest Radiol; 2016 Mar; 51(3):177-85. PubMed ID: 26561049
[TBL] [Abstract][Full Text] [Related]
20. Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer.
Mulligan AM; Pinnaduwage D; Tchatchou S; Bull SB; Andrulis IL
Cancer Immunol Res; 2016 Jan; 4(1):41-8. PubMed ID: 26546451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
